Instadose Pharma Corp. reported earnings results for the third quarter and nine months ended February 28, 2022. For the third quarter, the company reported net loss was USD 1.15 million compared to USD 13.3 million a year ago.

For the nine months, net loss was USD 37.81 million compared to USD 20.58 million a year ago. Basic loss per share from continuing operations was USD 0.07 compared to USD 0.04 a year ago. Diluted loss per share from continuing operations was USD 0.07 compared to USD 0.04 a year ago.